The DOI matches its Crossref record; 76 of the 76 references it cites were found in a registry or an index.
Epidemiology, Natural History, Risk Factors, and Prevention of Graves’ Orbitopathy
Open accessAbstract
GO is the most frequent extrathyroidal manifestation of Graves’ disease, although it may rarely occur in euthyroid/hypothyroid patients with chronic autoimmune thyroiditis. It is a relatively infrequent disorder, and men tend to have more severe ocular involvement at an older age. The prevalence of GO is lower than in the past among patients with recent onset Graves’ hyperthyroidism, and moderate-to-severe forms requiring aggressive treatments are no more than 5–6% of all cases of GO. After an initial inflammatory (active) phase and a phase of stabilization (plateau phase), GO tends to improve and eventually inactivates (inactive or burnt-out phase). Minimal-to-mild GO often remits spontaneously, but complete restitutio ad integrum almost never occurs when GO is more than mild. Several risk factors contribute to its development on a yet undefined genetic background. Cigarette smoking is the most important of them. Early diagnosis, control and removal of modifiable risk factors, early treatment of mild forms of GO may effectively limit the risk of progression to more severe forms, which have a profound and dramatic impact on the quality of life of affected individuals, and remain a therapeutic challenge, often requiring long-lasting and multiple medical and surgical therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bahn, R. S. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0905750 · Cited by 1,552
Smith, T. J., & Hegedüs, L. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1510030 · Cited by 1,257
Bartalena, L., Baldeschi, L., Boboridis, K., Eckstein, A., Kahaly, G. J., Marcocci, C., Perros, P., Salvi, M., & Wiersinga, W. M. (2016) · European Thyroid Journal · doi:10.1159/000443828 · Cited by 943
Self-citation2018 European Thyroid Association Guideline for the Management of Graves’ Hyperthyroidism
Kahaly, G. J., Bartalena, L., Hegedüs, L., Leenhardt, L., Poppe, K., & Pearce, S. H. (2018) · European Thyroid Journal · doi:10.1159/000490384 · Cited by 940
Self-citationTeprotumumab for Thyroid-Associated Ophthalmopathy
Smith, T. J., Kahaly, G. J., Ezra, D. G., Fleming, J. C., Dailey, R. A., Tang, R. A., Harris, G. J., Antonelli, A., Salvi, M., Goldberg, R. A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614949 · Cited by 756
Teprotumumab for the Treatment of Active Thyroid Eye Disease
Douglas, R. S., Kahaly, G. J., Patel, A., Sile, S., Thompson, E. H. Z., Perdok, R., Fleming, J. C., Fowler, B. T., Marcocci, C., Marinò, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1910434 · Cited by 752
Relation between Therapy for Hyperthyroidism and the Course of Graves' Ophthalmopathy
Bartalena, L., Marcocci, C., Bogazzi, F., Manetti, L., Tanda, M. L., Dell'Unto, E., Bruno-Bossio, G., Nardi, M., Bartolomei, M. P., Lepri, A., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801083380201 · Cited by 715
Self-citationManagement of Graves’ Ophthalmopathy: Reality and Perspectives*
Bartalena, L., Pinchera, A., & Marcocci, C. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.2.0393 · Cited by 677
Self-citationSelenium and the Course of Mild Graves' Orbitopathy
Marcocci, C., Kahaly, G. J., Krassas, G. E., Bartalena, L., Prummel, M., Stahl, M., Altea, M. A., Nardi, M., Pitz, S., Boboridis, K., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1012985 · Cited by 619
Self-citationOccurrence of Ophthalmopathy after Treatment for Graves' Hyperthyroidism
Tallstedt, L., Lundell, G., Tørring, O., Wallin, G., Ljunggren, J.-G., Blomgren, H., & Taube, A. (1992) · New England Journal of Medicine · doi:10.1056/nejm199206253262603 · Cited by 521
Smoking and Risk of Graves' Disease
Prummel, M. F. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1993.03500040045034 · Cited by 503
Eckstein, A. K., Plicht, M., Lax, H., Neuhäuser, M., Mann, K., Lederbogen, S., Heckmann, C., Esser, J., & Morgenthaler, N. G. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2813 · Cited by 477
Epidemiology and Prevention of Graves' Ophthalmopathy
Wiersinga, W. M., & Bartalena, L. (2002) · Thyroid · doi:10.1089/105072502761016476 · Cited by 458
Self-citationLaurberg, P., Wallin, G., Tallstedt, L., Abraham-Nordling, M., Lundell, G., & Tørring, O. (2008) · European Journal of Endocrinology · doi:10.1530/eje-07-0450 · Cited by 428
Wiersinga, W. M. (2013) · Clinical Endocrinology · doi:10.1111/cen.12222 · Cited by 389
Bartley, G. B. (1994) · PubMed · Cited by 363
Bartalena, L., & Tanda, M. L. (2009) · New England Journal of Medicine · doi:10.1056/nejmcp0806317 · Cited by 336
Self-citationTanda, M. L., Piantanida, E., Liparulo, L., Veronesi, G., Lai, A., Sassi, L., Pariani, N., Gallo, D., Azzolini, C., Ferrario, M., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3873 · Cited by 328
Self-citationAssociation of thyrotrophin receptor antibodies with the clinical features of Graves' ophthalmopathy
Gerding, M. N., van der Meer, J. W. C., Broenink, M., Bakker, O., Wiersinga, W. M., & Prummel, M. F. (2000) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2000.00959.x · Cited by 325
Bartalena, L., Marcocci, C., Bogazzi, F., Panicucci, M., Lepri, A., & Pinchera, A. (1989) · New England Journal of Medicine · doi:10.1056/nejm198911163212001 · Cited by 318
Self-citationNew insights into the pathogenesis and nonsurgical management of Graves orbitopathy
Taylor, P. N., Zhang, L., Lee, R. W. J., Muller, I., Ezra, D. G., Dayan, C. M., Kahaly, G. J., & Ludgate, M. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0305-4 · Cited by 315
Cigarette Smoking and Treatment Outcomes in Graves Ophthalmopathy
Bartalena, L., Marcocci, C., Tanda, M. L., Manetti, L., Dell'Unto, E., Bartolomei, M. P., Nardi, M., Martino, E., & Pinchera, A. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-129-8-199810150-00010 · Cited by 295
Self-citationPerros, P., Crombie, A. L., Matthews, J. N. S., & Kendall‐Taylor, P. (1993) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1993.tb00516.x · Cited by 288
Mechanisms of Autoimmune Thyroid Diseases: From Genetics to Epigenetics
Tomer, Y. (2014) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-012513-104713 · Cited by 274
Träisk, F., Tallstedt, L., Abraham-Nordling, M., Andersson, T., Berg, G., Calissendorff, J., Hallengren, B., Hedner, P., Lantz, M., Nyström, E., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0747 · Cited by 262
RUNDLE, F. F., & Wilson, C. W. (1945) · PubMed · Cited by 259
Influences of Age, Gender, Smoking, and Family History on Autoimmune Thyroid Disease Phenotype
Manji, N., Carr-Smith, J. D., Boelaert, K., Allahabadia, A., Armitage, M., Chatterjee, V. K., Lazarus, J. H., Pearce, S. H. S., Vaidya, B., Gough, S. C., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1402 · Cited by 255
Incidence of hyperthyroidism in Sweden
Abraham-Nordling, M., Byström, K., Törring, O., Lantz, M., Berg, G., Calissendorff, J., Nyström, H. F., Jansson, S., Jörneskog, G., Karlsson, F. A., et al. (2011) · European Journal of Endocrinology · doi:10.1530/eje-11-0548 · Cited by 251
Effect of Abnormal Thyroid Function on the Severity of Graves' Ophthalmopathy
Prummel, M. F. (1990) · Archives of Internal Medicine · doi:10.1001/archinte.1990.00390170124027 · Cited by 238
Pfeilschifter, J., & Ziegler, R. (1996) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1996.8220832.x · Cited by 227
Lytton, S. D., Ponto, K. A., Kanitz, M., Matheis, N., Kohn, L. D., & Kahaly, G. J. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2470 · Cited by 219
Natural history of thyroid associated ophthalmopathy
Perros, P., Cromble, A. L., & Kendall‐Taylor, P. (1995) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1995.tb02597.x · Cited by 219
Prummel, M., Bakker, A., Wiersinga, W., Baldeschi, L., Mourits, M., Kendall-Taylor, P., Perros, P., Neoh, C., Dickinson, A., Lazarus, J., et al. (2003) · European Journal of Endocrinology · doi:10.1530/eje.0.1480491 · Cited by 213
Impact of smoking on the response to treatment of thyroid associated ophthalmopathy
Eckstein, A. (2003) · British Journal of Ophthalmology · doi:10.1136/bjo.87.6.773 · Cited by 211
Prevalence of thyroid eye disease in Graves’ disease: A meta‐analysis and systematic review
Chin, Y. H., Ng, C. H., Lee, M. H., Koh, J. W. H., Kiew, J., Yang, S. P., Sundar, G., & Khoo, C. M. (2020) · Clinical Endocrinology · doi:10.1111/cen.14296 · Cited by 211
Graves’ ophthalmopathy in relation to cigarette smoking and ethnic origin
Tellez, M., Cooper, J., & Edmonds, C. (1992) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1992.tb01445.x · Cited by 202
More on smoking habits and Graves’ ophthalmopathy
Bartalena, L., Martino, E., Marcocci, C., Bogazzi, F., Panicucci, M., Velluzzi, F., Loviselli, A., & Pinchera, A. (1989) · Journal of Endocrinological Investigation · doi:10.1007/bf03350047 · Cited by 199
Self-citationGraves' Ophthalmopathy: Epidemiology and Natural History
Hiromatsu, Y., Eguchi, H., Tani, J., Kasaoka, M., & Teshima, Y. (2014) · Internal Medicine · doi:10.2169/internalmedicine.53.1518 · Cited by 191
Twin studies as a model for exploring the aetiology of autoimmune thyroid disease
Brix, T. H., & Hegedüs, L. (2012) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2011.04318.x · Cited by 185
Risk Factors for Developing Thyroid-Associated Ophthalmopathy Among Individuals With Graves Disease
Stein, J. D., Childers, D., Gupta, S., Talwar, N., Nan, B., Lee, B. J., Smith, T. J., & Douglas, R. (2015) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2014.5103 · Cited by 183
Epidemiology of Graves’ orbitopathy (GO) and relationship with thyroid disease
Lazarus, J. H. (2012) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2011.10.005 · Cited by 182 · cited 1×
“Previous approximate calculations yielded an estimate of GO prevalence in Europe ranging from 100 to 305/100,000 population (16).”
BackgroundStudies on the occurrence of ophthalmopathy in Graves' disease
Marcocci, C., Bartalena, L., Bogazzi, F., Panicucci, M., & Pinchera, A. (1989) · Acta Endocrinologica · doi:10.1530/acta.0.1200473 · Cited by 172
Self-citationPerros, P., Hegedüs, L., Bartalena, L., Marcocci, C., Kahaly, G. J., Baldeschi, L., Salvi, M., Lazarus, J. H., Eckstein, A., Pitz, S., et al. (2017) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-017-0625-1 · Cited by 172
Self-citationEckstein, A. K., Lösch, C., Glowacka, D., Schott, M., Mann, K., Esser, J., & Morgenthaler, N. G. (2009) · British Journal of Ophthalmology · doi:10.1136/bjo.2007.137265 · Cited by 158
Perros, P., Kendall-Taylor, P., Neoh, C., Frewin, S., & Dickinson, J. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-0507 · Cited by 156
Role of genetic and non-genetic factors in the etiology of Graves’ disease
Marinò, M., Latrofa, F., Menconi, F., Chiovato, L., & Vitti, P. (2014) · Journal of Endocrinological Investigation · doi:10.1007/s40618-014-0214-2 · Cited by 142
Khoo, D. H. C., Ho, S.-C., Seah, L. L., Fong, K. S., Tai, E. S., Chee, S.-P., Eng, P., AW, S. E., & Fok, A. C. K. (1999) · Thyroid · doi:10.1089/thy.1999.9.1175 · Cited by 139
Khoo, D. H. C., Eng, P., Ho, S.-C., Tai, E. S., Morgenthaler, N. G., Seah, L. L., Fong, K. S., Chee, S.-P., Choo, C. T., & Aw, S. E. (2000) · Thyroid · doi:10.1089/thy.2000.10.1093 · Cited by 137
Laurberg, P., Berman, D. C., Bülow Pedersen, I., Andersen, S., & Carlé, A. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-1275 · Cited by 133
Kahaly, G. J., Diana, T., Glang, J., Kanitz, M., Pitz, S., & König, J. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1220 · Cited by 132
Lai, A., Sassi, L., Compri, E., Marino, F., Sivelli, P., Piantanida, E., Tanda, M. L., & Bartalena, L. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2130 · Cited by 129
Self-citationPerros, P., Žarković, M., Azzolini, C., Ayvaz, G., Baldeschi, L., Bartalena, L., Boschi, A., Bournaud, C., Brix, T. H., Covelli, D., et al. (2015) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2015-306733 · Cited by 124
Self-citationKhong, J. J., Finch, S. J., Silva, C. D., Rylander, S., Craig, J. E., Selva, D. N., & Ebeling, P. R. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-4294 · Cited by 124
Prevalence and natural history of Graves' orbitopathy in the XXI century.
Piantanida, E., Tanda, M. L., Lai, A., Sassi, L., & Bartalena, L. (2013) · PubMed · doi:10.3275/8937 · Cited by 122
Self-citationSabini, E., Mazzi, B., Profilo, M. A., Mautone, T., Casini, G., Rocchi, R., Ionni, I., Menconi, F., Leo, M., Nardi, M., et al. (2018) · Thyroid · doi:10.1089/thy.2017.0430 · Cited by 118
Childhood Graves’ ophthalmopathy: results of a European questionnaire study
Krassas, G. E., Segni, M., & Wiersinga, W. M. (2005) · European Journal of Endocrinology · doi:10.1530/eje.1.01991 · Cited by 114
Spontaneous Improvement of Untreated Mild Graves' Ophthalmopathy: Rundle's Curve Revisited
Menconi, F., Profilo, M. A., Leo, M., Sisti, E., Altea, M. A., Rocchi, R., Latrofa, F., Nardi, M., Vitti, P., Marcocci, C., et al. (2013) · Thyroid · doi:10.1089/thy.2013.0240 · Cited by 111
Prevention of Graves’ ophthalmopathy
Bartalena, L. (2012) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2011.09.004 · Cited by 103
Self-citationWiersinga, W. M., Žarković, M., Bartalena, L., Donati, S., Perros, P., Okosieme, O. E., Morris, D. S., Fichter, N., Lareida, J., von Arx, G., et al. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0039 · Cited by 102
Self-citationNatural History of Thyroid Eye Disease
Perros, P., & Kendall‐Taylor, P. (1998) · Thyroid · doi:10.1089/thy.1998.8.423 · Cited by 89
Relationship Between Graves' Ophthalmopathy and Type of Treatment of Graves' Hyperthyroidism
Marcocci, C., Bartalena, L., Bogazzi, F., Bruno-Bossio, G., & Pinchera, A. (1992) · Thyroid · doi:10.1089/thy.1992.2.171 · Cited by 89
Self-citationNicolì, F., Lanzolla, G., Mantuano, M., Ionni, I., Mazzi, B., Leo, M., Sframeli, A. T., Posarelli, C., Maglionico, M. N., Figus, M., et al. (2020) · Journal of Endocrinological Investigation · doi:10.1007/s40618-020-01353-y · Cited by 86
Relationship between serum cholesterol and Graves’ orbitopathy (GO): a confirmatory study
Lanzolla, G., Sabini, E., Profilo, M. A., Mazzi, B., Sframeli, A. T., Rocchi, R., Menconi, F., Leo, M., Nardi, M., Vitti, P., et al. (2018) · Journal of Endocrinological Investigation · doi:10.1007/s40618-018-0915-z · Cited by 84
Ponto, K. A., Binder, H., Diana, T., Matheis, N., Otto, A. F., Pitz, S., Pfeiffer, N., & Kahaly, G. J. (2015) · Thyroid · doi:10.1089/thy.2015.0031 · Cited by 83
Oxidative stress and Graves' ophthalmopathy: In vitro studies and therapeutic implications
Bartalena, L., Tanda, M. L., Piantanida, E., & Lai, A. (2003) · BioFactors · doi:10.1002/biof.5520190308 · Cited by 80
Self-citationOrbital diseases mimicking graves’ orbitopathy: a long-standing challenge in differential diagnosis
Marinò, M., Ionni, I., Lanzolla, G., Sframeli, A. T., Latrofa, F., Rocchi, R., & Marcocci, C. (2019) · Journal of Endocrinological Investigation · doi:10.1007/s40618-019-01141-3 · Cited by 74
Ten-year follow-up of thyroid epidemiology in Slovenia after increase in salt iodization
Zaletel, K., Gaberšček, S., Pirnat, E., Krhin, B., & Hojker, S. (2011) · Croatian Medical Journal · doi:10.3325/cmj.2011.52.615 · Cited by 65
Yin, X., Latif, R., Bahn, R. S., & Davies, T. F. (2012) · Thyroid · doi:10.1089/thy.2012.0007 · Cited by 59
Graves' ophtalmopathy: natural history and treatment outcomes
Noth, D., & Gebauer, M. (2001) · Swiss Medical Weekly · doi:10.4414/smw.2001.09781 · Cited by 51
Vannucchi, G. M., Covelli, D., Campi, I., Currò, N., Dazzi, D., Rodari, M., Pepe, G., Chiti, A., Guastella, C., Lazzaroni, E., et al. (2019) · Thyroid · doi:10.1089/thy.2019.0150 · Cited by 45
The European Group on Graves’ Orbitopathy, Perros, P., Žarković, M., Panagiotou, G., Azzolini, C., Ayvaz, G., Baldeschi, L., Bartalena, L., Boschi, A., Nardi, M., et al. (2020) · Journal of Endocrinological Investigation · doi:10.1007/s40618-020-01258-w · Cited by 37
Self-citationGraves ’ ophthalmopathy: natural history and treatment outcomes
Noth, D., Gebauer, M., Müller, B., Bürgi, U., & Diem, P. (2001) · Bern Open Repository and Information System (University of Bern) · Cited by 26
Rotondi, M., Virili, C., Pinto, S., Coperchini, F., Croce, L., Brusca, N., Centanni, M., & Chiovato, L. (2019) · Journal of Endocrinological Investigation · doi:10.1007/s40618-019-01094-7 · Cited by 22
Rosetti, S., Tanda, M. L., Veronesi, G., Masiello, E., Premoli, P., Gallo, D., Cusini, C., Donati, S., Sabatino, J., Ippolito, S., et al. (2019) · Journal of Endocrinological Investigation · doi:10.1007/s40618-019-01126-2 · Cited by 21
Self-citationNatural history of graves’ orbitopathy after treatment
Menconi, F., Leo, M., Sabini, E., Mautone, T., Nardi, M., Sainato, A., Sellari‐Franceschini, S., Vitti, P., Marcocci, C., & Marinò, M. (2016) · Endocrine · doi:10.1007/s12020-016-1136-x · Cited by 19
Bartalena, L. (2017) · KARGER eBooks · doi:10.1159/000475968 · Cited by 2
Self-citation
Cited by
Bartalena, L., Kahaly, G. J., Baldeschi, L., Dayan, C. M., Eckstein, A., Marcocci, C., Marinò, M., Vaidya, B., Wiersinga, W. M., _, _., et al. (2021) · European Journal of Endocrinology · doi:10.1530/eje-21-0479 · Cited by 1,054
Self-citation
Metadata
- Authors
- Bartalena, L., Piantanida, E., Gallo, D., Lai, A., & Tanda, M. L.
- Venue
- Frontiers in Endocrinology
- Publisher
- Frontiers Media SA
- Published
- 2020-11-30
- Volume
- 11
- Pages
- 615993-615993
- ISSN
- 1664-2392 (ISSN-L)
- OpenAlex
- W3107470055
- Cited by
- 369
- References
- 76
- FWCI
- 19.18
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.